Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours Β· Estimated delivery Aug 29 - Sep 3
A once-daily oral small-molecule GLP-1 receptor agonist delivered progressive, dose-dependent weight loss without food or fluid restrictions, supporting larger phase 3 trials for long-term weight management
The exact mechanism for weight loss is not fully understood, but reduced energy intake is the primary driver
Almost comparable to whats seen with some surgical interventions: Participants lost up to 20.9% of their body weight on the highest dose (15 mg) 91% lost at least 5% of their body weight More than half lost 20% or more, and over a third dropped 25% or more Waist size, blood pressure, insulin resistance, and cholesterol all improved Most side effects (like nausea or constipation) were mild and appeared mostly during the dose adjustment phase
We are all comfortable with the new user-friendly injectable pens and it certainly makes the uptake of injectables by patients so much easier
US$ 21.49
US$ 29.76
US$ 26.43
US$ 28.96
US$ 25.26
